{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:57:55Z","timestamp":1776239875111,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10627-1","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:15:24Z","timestamp":1776237324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie"],"prefix":"10.1007","volume":"31","author":[{"given":"Matteo","family":"Busti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Enrico","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalliopi","family":"Keramida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamas","family":"Alexy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avishay","family":"Grupper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savina","family":"Nodari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dike B.","family":"Ojji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia O.","family":"Guimaraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Musella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Monzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"10627_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105447","volume":"109","author":"T Eroglu","year":"2024","unstructured":"Eroglu T, Capone F, Schiattarella GG (2024) The evolving landscape of cardiometabolic diseases. EBioMedicine 109:105447","journal-title":"EBioMedicine"},{"issue":"7","key":"10627_CR2","doi-asserted-by":"publisher","first-page":"e006260","DOI":"10.1161\/CIRCOUTCOMES.119.006260","volume":"13","author":"B Zareini","year":"2020","unstructured":"Zareini B, Blanche P, D\u2019Souza M, Elmegaard Malik M, Norgaard CH, Selmer C et al (2020) Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study. Circ Cardiovasc Qual Outcomes 13(7):e006260","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"10627_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02609-8","volume":"24","author":"L Monzo","year":"2025","unstructured":"Monzo L, Kobayashi M, Ferreira JP, Lamiral Z, Delles C, Clark AL et al (2025) Echocardiographic and biomarker characteristics in diabetes, coronary artery disease or both: insights from HOMAGE trial. Cardiovasc Diabetol 24(1):111","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10627_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT et al (2025) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 13(1):15\u201328","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10627_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA (2022) Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol 21(1):169","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10627_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E et al (2025) Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 393(1):26\u201336","journal-title":"N Engl J Med"},{"issue":"5","key":"10627_CR7","volume":"4","author":"SS Dani","year":"2025","unstructured":"Dani SS, Makwana B, Khadke S, Kumar A, Jhund P, Nasir K et al (2025) An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like peptide-1 receptor agonists. JACC: Advances 4(5):101740","journal-title":"JACC: Advances"},{"issue":"24","key":"10627_CR8","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE et al (2025) Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med 393(24):2409\u201320","journal-title":"N Engl J Med"},{"issue":"10","key":"10627_CR9","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/ejhf.2670","volume":"24","author":"KRH Branch","year":"2022","unstructured":"Branch KRH, Dagenais GR, Avezum A, Basile J, Conget I, Cushman WC et al (2022) Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial. Eur J Heart Fail 24(10):1805\u201312","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10627_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","volume":"75","author":"SP Marso","year":"2020","unstructured":"Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA et al (2020) Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol 75(10):1128\u201341","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10627_CR11","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1002\/ejhf.70082","volume":"27","author":"L Monzo","year":"2025","unstructured":"Monzo L, Savarese G, Mullens W, Abdin A, Bozkurt B, Chioncel O et al (2025) Pharmacological treatment for patients with obesity and heart failure: focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document. Eur J Heart Fail 27(11):2465\u201379","journal-title":"Eur J Heart Fail"},{"key":"10627_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Bhatt DL, Buse JB, Prato DS, Kahn SE, Lincoff AM et al (2024) Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J 267:1\u201311","journal-title":"Am Heart J"},{"key":"10627_CR13","unstructured":"U.S. Food and Drug Administration. Guidance for industry. Non-inferiority clinical trials to establish effectiveness. (2016) [Available from: https:\/\/www.fda.gov\/media\/78504\/download"},{"issue":"10193","key":"10627_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130","journal-title":"Lancet"},{"issue":"1","key":"10627_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12933-022-01601-w","volume":"21","author":"DK McGuire","year":"2022","unstructured":"McGuire DK, D\u2019Alessio D, Nicholls SJ, Nissen SE, Riesmeyer JS, Pavo I et al (2022) Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. Cardiovasc Diabetol 21(1):163","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10627_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503\u201315","journal-title":"N Engl J Med"},{"key":"10627_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04102-x","author":"N Kruger","year":"2025","unstructured":"Kruger N, Schneeweiss S, Desai RJ, Sreedhara SK, Kehoe AR, Fuse K et al (2025) Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-04102-x","journal-title":"Nat Med"},{"issue":"1","key":"10627_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69\u201377","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10627_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R et al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500\u20138","journal-title":"JAMA"},{"issue":"1","key":"10627_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/dom.14862","volume":"25","author":"JS Neves","year":"2023","unstructured":"Neves JS, Vasques-Novoa F, Borges-Canha M, Leite AR, Sharma A, Carvalho D et al (2023) Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial. Diabetes Obes Metab 25(1):189\u201397","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10627_CR21","doi-asserted-by":"publisher","first-page":"102489","DOI":"10.1016\/j.jchf.2025.03.035","volume":"13","author":"JS Neves","year":"2025","unstructured":"Neves JS, Vale C, Leite AR, Leite-Moreira A, Zannad F, Butler J et al (2025) GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction: Meta-Analysis of Randomized Clinical Trials. JACC Heart Fail 13(7):102489","journal-title":"JACC Heart Fail"},{"issue":"10454","key":"10627_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D et al (2024) Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 404(10454):773\u201386","journal-title":"Lancet"},{"issue":"9","key":"10627_CR23","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1111\/dom.14762","volume":"24","author":"DA Cox","year":"2022","unstructured":"Cox DA, Wang H, Nicolay C, Bethel MA (2022) Effect of expanded dulaglutide weekly doses (3.0\u00a0mg and 4.5\u00a0mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study. Diabetes Obes Metab 24(9):1770\u20131778","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10627_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389(12):1069\u201384","journal-title":"N Engl J Med"},{"issue":"15","key":"10627_CR25","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK et al (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 390(15):1394\u2013407","journal-title":"N Engl J Med"},{"issue":"5","key":"10627_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V et al (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 392(5):427\u201337","journal-title":"N Engl J Med"},{"issue":"Suppl C","key":"10627_CR27","doi-asserted-by":"publisher","first-page":"C309","DOI":"10.1093\/eurheartjsupp\/suad055","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Ferrari I, Cicogna F, Tota C, Cice G, Girerd N et al (2023) Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians. Eur Heart J Suppl 25(Suppl C):C309\u2013C15","journal-title":"Eur Heart J Suppl"},{"issue":"1","key":"10627_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.53323","volume":"9","author":"Z Wang","year":"2026","unstructured":"Wang Z, Wang L, Zhang X, Lowery BD, Shaffer LL, Chen Y et al (2026) Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists. JAMA Netw Open 9(1):e2553323","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10627_CR29","first-page":"315","volume":"13","author":"L Monzo","year":"2025","unstructured":"Monzo L, Jarolim P, Borlaug BA, Benes J, Jurcova I, Jenca D et al (2025) Growth Differentiation Factor-15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure. JACC: Heart Failure 13(2):315\u201329","journal-title":"JACC: Heart Failure"},{"issue":"16","key":"10627_CR30","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","volume":"150","author":"J Linge","year":"2024","unstructured":"Linge J, Birkenfeld AL, Neeland IJ (2024) Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation 150(16):1288\u20131298","journal-title":"Circulation"},{"issue":"10456","key":"10627_CR31","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ et al (2024) Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 404(10456):949\u201361","journal-title":"Lancet"},{"issue":"14","key":"10627_CR32","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.2025.14092","volume":"334","author":"N Kruger","year":"2025","unstructured":"Kruger N, Schneeweiss S, Fuse K, Matseyko S, Sreedhara SK, Hahn G et al (2025) Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction. JAMA 334(14):1255\u201366","journal-title":"JAMA"},{"key":"10627_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/eschf\/xvag042","author":"L Monzo","year":"2026","unstructured":"Monzo L, Savarese G, Duarte K, Baudry G, Petrie MC, Girerd N (2026) Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network. ESC Heart Fail 13(1):xvag042. https:\/\/doi.org\/10.1093\/eschf\/xvag042","journal-title":"ESC Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10627-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10627-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10627-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:15:27Z","timestamp":1776237327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10627-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10627"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10627-1","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.E.C. receives salary support from CPC, a non-profit academic research organization affiliated with the University of Colorado. Y.S. reports lecture fees from AstraZeneca, Ono Pharmaceutical, Eli Lilly, and NovoNordisk. A.L.S. has received research grants from AstraZeneca, Glaxo Smith Kline, Novartis and RACE Oncology; and honoraria from Novartis, Eli Lilly, Bayer, AstraZeneca, Janssen, Cipla, Glaxo Smith Kline, Novo Nordisk and Boehringer Ingelheim. P.O.G. reports lecture fees from Libbs Pharmaceuticals. A.P.A. has received relevant research support through grants to his institution from the National Institutes of Health (R01HL173866 and R01AG091005), the Food and Drug Administration (U01FD008704), The American Heart Association, The Permanente Medical Group, Kaiser Permanente Northern California Community Benefits Programs, Garfield Memorial Fund, Abbott Laboratories, Abiomed, Amarin Pharma, Inc., Bayer Pharma AG, Boehringer Ingelheim, Cordio Medical, Edwards Lifesciences LLC, Esperion Therapeutics, Inc., Merck, and Novartis. Consulting for Bristol Meyer Squibb, Bayer Pharma AG, Corstasis, Merck, Novo Nordisk, Pharmacosmos A\/S, Pfizer, scPharma, SQ Innovation, Reprieve Cardiovascular, and VisCardia. N.G. reports honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Novartis, NovoNordisk, Roche Diagnostics, NP Medical and Echosens. L.M. reports a travel grant from Boehringer Ingelheim. All conflicts of interest have been declared outside the present work. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}